INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
Abstract
Summary. The aim of the present research was to study the influence of еpoetin alfa to the level of pro- and anti-inflammatory cytokines in patients with anemia treated by hemodialysis (HD).
Materials and methods: We examined 73patients with anemia treated by hemodialysis (mean age 45,85 ±1,21 years). Patients were divided into 2groups: I group - comparison (n = 32), II group - treatment by epoetin alfa (n = 41). The levels of hemoglobin, C-reactiveprotein, ferritin, albumin, pro-and anti-inflammatory cytokines were determined before and after treatment in patients of both groups. The duration of treatment was 5 months.
Results: Epoetin alfa increases Hb levels in patients treated by HD. After epoetin alfa applying reduction of proinflammatory cytokines ( TNF -a, IL -ip, IL -17, IL -18) and increased levels of IL -10 were observed.
Conclusions: The clinical efficacy of the epoetin alfa treatment at the moment of completion of treatment was 75.6% (level of Hb > 110 g/L ). Epoetin alfa, improving the level of Hb, reduces the activity of chronic inflammation.
Downloads
References
Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) / F. Locatelli, R. L. Pirsoni, C. Combe [et al.] // Nephrol. Dial. Transplant. – 2004. – Vol. 19, № 1. - P. 121-132.
Biomarkers in kidney and heart disease / A. S. Maisel, N. Katz, H. L. Hillege [et al.] // Nephrol. Dial. Transplant. - 2011. - Vol. 26, № 1. - Р. 62-74.-4
Chronic Inflammation and Mortality in Haemodialysis: Effect of Different Renal Replacement Therapies. Results from the RISCAVID Study / V. Panichi, G. M. Rizza, S. Paoletti [et al.] // Nephrol. Dial. Transplant. - 2008. - Vd 23, № 7. - Р. 2337-2343.
Functional Promoter Haplotypes of Interleukin-18 Condition Susceptibility to Severe Malarial Anemia and Childhood Mortality / S. B. Anyona, P. Kempaiah, E. Raballah [et al.] // Infect. Immun. - 2011. - Vol. 79, № 12. - Р. 4923-4932.
IL-18 is involved in vascular injury in end-stage renal disease patients / Т. Porazko, J. Kuzniar, M. Kuzstal [et al.] // Nephrol. Dial. Transplant. - 2009. - Vol. 24, № 2. - P. 589-596.
Interleukin-10 inhibits erythropoietin-independent growth of erythroid bursts in patients with polycythemia vera / K. L. Geissler, L.Ohler, M. Fodinger [et al.] // Blood. - 1998. - Vol. 92. - P.1967-1972.
Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice / К. Danzaki, Y. Matsui, M. Ikesue [et al.] // Arterioscler Thromb. Vasc. Biol. - 2012. - Vol. 32, № 2. - Р. 273-280.
OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) / W.H. Horl, Y. Vanrenterghem, B. Canaud [et al.] // Nephrol. Dial. Transplant. - 2007. - Vol. 22, № 3. - Р. 20-26.
Production of the effector cytokine interleukin-17, rather than interferon-y, is more strongly associated with autoimmune hemolytic anemia / A. M. Hall, O. M. Zamzami, N. Whibley [et al. ] // Haematologica. – 2012. - Vol. 97, № 10. - P. 1494-1500.
The study of IL-18 and IL-18 BP balance in aplastic anemia / N. N. Shan, Y.J. Jiang, X. H. Sui [et al.] // Infect. Immun. - 2011. - Vol. 32, № 11. - P. 783-785.
Th17 immune responses contribute to the pathophysiology of aplastic anemia / R. P. de Latour, V. Visconte, T. Takaku [et al.] // Blood. – 2010. – Vol. 116. - P. 4175-4184.
Role of IL-10 for Induction of Anemia During Inflammation / H. Tilg, H. Ulmer, A. Kaser [et al.] // J. Immunol. - 2002. - Vol. 169, № 4. - P. 22042209.
